京都大学：将 iPS 免疫细胞移植到癌症患者中：
-京都大学等开始临床试验-
京都大学
国家癌症中心
11月11日，它宣布已将iPS细胞制成的免疫细胞移植到卵巢癌患者体内。
使用 iPS 细胞治疗癌症：
这是继千叶大学等团队之后，第二次使用 iPS 细胞进行癌症治疗。
这一次，临床试验的主要目的是考察安全性和副作用，到目前为止还没有患者出现排斥反应。
卵巢癌患者：
患者是一名 50 多岁的女性，在国立癌症中心东医院就诊。
患者患有复发性卵巢癌，
癌细胞也散布在腹膜中，
没有有效的治疗方法。
注射 iPS 自然杀伤细胞：
京都大学已经生产了 1000 万个由 iPS 细胞制成的免疫细胞自然杀伤细胞。
9月在患处附近腹腔注射3次。
我们预计免疫细胞会攻击癌细胞。
朝日新闻数码
https://www.asahi.com/articles/ASPCC528LPCCPLBJ005.html
Clinical trial starts for iPS cancer treatment
NHK WORLD-JAPAN News
Researchers in Japansay they have started a clinical trial of ovarian cancer treatment involving immune cells created from induced pluripotent stem cells, or IPS cells.
The team of researchers from the National Cancer Center Hospital East and Kyoto University’s Center for iPS Cell Research and Application
made the announcement in an online news conference on Thursday.
The iPS cells used in the treatment
are capable of developing into any kind of cell.A gene that reacts strongly to a protein unique to a certain type of ovarian cancer is inserted into iPS cells to create natural killer cells.
These NK cells
will then be injected into the ovaries of patients with this type of ovarian cancer.The team says
it does not expect the treatment to cause serious side effects because NK cells attack cancer cells but seldom affect normal ones.The team plans to conduct a clinical trial of the treatment on up to 18 patients with advanced cases of ovarian cancer that are no longer operable.
They will be administered NK cells once a week, for a maximum of four times, to determine the safety and efficacy of the treatment.
In the first case, a patient in her 50s underwent three sessions in September, and has reportedly shown no adverse reactions since then.
Dr Doi Toshihiko of the National Cancer Center Hospital East
says his team aims to confirm the safety of the therapy, and will then work out a set of rules for the storage and transportation of NK cells, as the next step toward making the treatment widely available.
In a separate development last year, another group of researchers in Japan, involving the RIKEN research institute and Chiba University,
started a clinical trial of cancer treatment using another type of immune cell — natural killer T cells, generated by iPS cells.